June 22 (Reuters) - Kazia Therapeutics Ltd KZA.AX :
* KAZIA PRESENTS FURTHER PAXALISIB AND CANTRIXIL DATA AT AACR, REINFORCING POSITIVE EFFICACY SIGNALS FOR BOTH DRUGS
* KAZIA THERAPEUTICS LTD - PROGRESSION-FREE SURVIVAL FOR PAXALISIB IS 8.5 MONTHS, VERSUS 8.4 MONTHS IN PREVIOUS ANALYSIS
* KAZIA THERAPEUTICS LTD - PAXALISIB OVERALL SURVIVAL (OS) REMAINS AT 17.7 MONTHS, IN LINE WITH ASCO DATA
* KAZIA THERAPEUTICS LTD - CANTRIXIL DATA SHOWS ONE COMPLETE RESPONSE TO TREATMENT, MEANING NO MEASURABLE DISEASE
* KAZIA THERAPEUTICS LTD - NEW RESULTS FOR CANTRIXIL WILL HELP CO TO EXPLORE PARTNERING OPPORTUNITIES OVER H2 OF YEAR
* KAZIA THERAPEUTICS LTD - EXPECTS TO COMPLETE PAXALISB PHASE II STUDY IN 1H CY2021
* KAZIA THERAPEUTICS LTD - FINAL DATA OF CANTRIXIL PHASE I STUDY EXPECTED IN H2 OF 2020